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Introduction
Bone is a dynamic tissue, composed of cells, collage-
nous matrix, and inorganic elements. The growth,
development, and maintenance of bone is a highly reg-
ulated process (1). It undergoes continuous remodel-
ing with a balance between bone resorption and for-
mation under normal conditions, involving coordinate
regulation of bone-forming cells (osteoblasts) and
bone-resorbing cells (osteoclasts) (2, 3). These cells arise
from hematopoietic precursors by physiologically con-
trolled processes that involve cytokines, growth factors,
and hormones (3, 4). Osteoclasts are rarely seen under
normal conditions, however, increased osteoclast activ-
ity is seen in many pathological disorders, including
Paget’s disease, lytic bone metastases, postmenopausal
osteoporosis, or rheumatoid arthritis (RA), leading to
net loss of bone.
RA is a chronic inflammatory joint disease, and
bone erosion is a major complication (5, 6). In areas
of pannus infiltration, erosion of calcified cartilage
and subchondral bone is common, leading to charac-
teristic marginal erosions seen radiographically in this
disease. The area of contact between pannus and car-
tilage/bone represents an erosive front, and the role
of osteoclasts in erosion of bone in arthritis has been
documented (7–10).
IL-1 and TNF- a are key mediators in the perpetua-
tion of synovitis and cartilage/bone destruction and are
produced in increased quantities by RA synovium and
detected in synovial fluid (11, 12). These proinflam-
matory cytokines mediate the cascade of molecular
pathways ensuing in the production of matrix-degrad-
ing enzymes (13). The important role of IL-1 b , TNF- a ,
and IL-6 on osteoclastic recruitment, proliferation, and
differentiation has been shown (14–17). In addition,
osteoclast or osteoclast-like cells demonstrated
immunoreactivity for IL-1b , IL-6, and TNF-a (18). Fur-
thermore, the potency of IL-17 as a stimulator of osteo-
clastogenesis has been shown in vitro (19), and this T-
cell–derived cytokine was found in the synovium of
patients with RA (19, 20). Recently, osteoprotegerin lig-
and (OPGL) has been considered a novel key regulator
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Bone destruction is the most difficult target in the treatment of rheumatoid arthritis (RA). Here,
we report that local overexpression of IL-4, introduced by a recombinant human type 5 adenovirus
vector (Ad5E1mIL-4) prevents joint damage and bone erosion in the knees of mice with collagen
arthritis (CIA). No difference was noted in the course of CIA in the injected knee joints between
Ad5E1mIL-4 and the control vector, but radiographic analysis revealed impressive reduction of
joint erosion and more compact bone structure in the Ad5E1mIL-4 group. Although severe
inflammation persisted in treated mice, Ad5E1mIL-4 prevented bone erosion and diminished tar-
trate-resistant acid phosphatase (TRAP) activity, indicating that local IL-4 inhibits the formation
of osteoclast-like cells. Messenger RNA levels of IL-17, IL-12, and cathepsin K in the synovial tis-
sue were suppressed, as were IL-6 and IL-12 protein production. Osteoprotegerin ligand (OPGL)
expression was markedly suppressed by local IL-4, but no loss of OPG expression was noted with
Ad5E1mIL-4 treatment. Finally, in in vitro studies, bone samples of patients with arthritis revealed
consistent suppression by IL-4 of type I collagen breakdown. IL-4 also enhanced synthesis of type
I procollagen, suggesting that it promoted tissue repair. These findings may have significant impli-
cations for the prevention of bone erosion in arthritis.
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of osteoclastogenesis, as OPGL knockout mice did not
show osteoclastic bone resorption (21).
In addition to the action of destructive mediators, the
destructive process seems under the control of regula-
tory mediators such as IL-4 and IL-10. These modula-
tory cytokines have the potential to antagonize inflam-
matory and destructive mediators of the RA process
effectively (22, 23). Marked protection of cartilage can
be achieved with IL-4/IL-10 treatment (24, 25). Recent-
ly, we found impressive prevention of cartilage destruc-
tion by local IL-4 gene therapy, despite severe inflam-
mation (26). Of great importance, IL-4 could not be
detected in the synovium of patients with RA (27). This
lack of IL-4 may contribute to the uneven balance
between destructive and regulatory mediators in the
synovium of the RA process. In vitro, IL-4 has been
shown to be an inhibitor of bone resorption (28–31)
and osteoclast-like cell formation (32, 33); however, its
role in vivo has not been identified.
In the present study, we examined the impact of local
IL-4 on bone erosion in the knee joint of mice with col-
lagen-induced arthritis, using gene transfer with an IL-
4–expressing adenoviral vector. In addition, we investi-
gated the effects of IL-4 on the degradation and
formation of collagen type I in bone samples from
patients with arthritis. Collagen arthritis is an autoim-
mune model of RA, driven by the combination of cel-
lular and humoral immunity against collagen type II
(CII) and is characterized by rapid and severe erosions
of cartilage and bone (34–36). Local IL-4 treatment
impressively prevents joint damage and bone erosion,
despite severe inflammation. The protective effect was
associated with decreased formation of osteoclast-like
cells and downregulation of IL-17, IL-6, IL-12, and
OPGL in the synovium. In addition, mRNA levels of
cathepsin K in synovial tissue was reduced in the IL-4
group. Interestingly, IL-4 prevented collagen type I
breakdown, but enhanced the formation of type I pro-
collagen in bone from patients with arthritis, suggest-
ing promotion of tissue repair.
Methods
Animals. Male DBA-1/BOM mice were purchased from
Bomholdgärd (Ry, Denmark). The mice were housed in
filter-top cages. The mice were immunized 10–12 weeks
of age. Female C57bl/6 and balb/c mice were obtained
at our university breeding facilities in Nijmegen. Balb/c
IL-4 gene knockout mice were kindly provided by NV
Organon (Oss, The Netherlands). Water and food were
provided ad libitum.
Adenoviral vectors. The recombinant replication-defi-
cient adenovirus Ad5E1mIL-4 was generated by homol-
ogous recombination after cotransfecting 293 cells with
PACCMVmIL-4 and a virus-rescuing vector pAdBHG10
as described elsewhere (37). The empty recombinant
replication-deficient adenovirus Ad5del70-3 was used as
a control vector throughout the study. High titers of
recombinant adenoviruses were amplified, purified,
titered, and stored as described previously (38). Biologic
activity of IL-4 produced by Ad5E1mIL-4 was verified by
blocking experiments with anti–IL-4 on AdE1mIL-
4–induced inflammation and synovial cell mass.
Intra-articular gene transfer with Ad5E1mIL-4. Naive
mice were intra-articularly injected in the right knee
joint with 108, 107, or 106 pfu/6 m L of either
Ad5E1mIL-4 or Ad5del70-3. At different time points,
mice were bled and sacrificed by cervical dislocation.
Patella with adjacent synovium was dissected in a
standardized manner (25) from the right and the con-
tralateral knee. The levels of IL-4 in sera and washouts
of joint tissue were measured by ELISA as described
later here.
Induction of collagen-induced arthritis. Bovine type II col-
lagen was prepared as described (24) and diluted in
0.05 M acetic acid to a concentration of 2 mg/mL and
was emulsified in equal volumes of CFA (2 mg/mL of
Mycobacterium tuberculosis; strain H37Ra; Difco Labora-
tories, Detroit, Michigan, USA). The mice were immu-
nized intradermally at the base of the tail with 100 m L
of emulsion (100 m g of collagen). On day 21, mice were
given an intraperitoneal booster injection of 100 m g of
type II collagen dissolved in PBS, and normally arthri-
tis onset will then occur around days 25–28.
Study protocol. The collagen arthritis model (CIA) was
induced in male DBA-1 mice as already described here.
Just before expected onset of CIA, mice were scored
visually for the appearance of arthritis. Mice without
macroscopic signs of arthritis in the paws were select-
ed. Mice were anesthetized with ether, and a small aper-
ture in the skin of the knee was performed for the intra-
articular injection procedure. When absence of arthritis
was confirmed in the knee joint, intra-articular injec-
tions were performed with 107 pfu/6 m L of either an IL-
4–expressing (Ad5E1mIL-4) or an empty control
(Ad5del70-3) recombinant human type 5 adenovirus
vector or with saline (26). At days 1, 3, 5, and 7 after the
intra-articular injection of the viral vector, mice were
sacrificed by cervical dislocation, and the skin of the
knee joint was removed. The appearance of arthritis in
the injected joints was assessed and severity score was
recorded as described previously (24). Thereafter, knee
joints were isolated and processed for light microscopy.
Assessment of arthritis. Mice were considered to have
arthritis when significant changes in redness and/or
swelling were noted in the digits or in other parts of the
paws. Knee joint inflammation was scored visually
after skin dissection, using the following scale: 0, non-
inflamed; 1, mild inflammation; 1.5, marked inflam-
mation; 2, severe inflammation. Scoring was done by
two independent observers, without knowledge of the
experimental groups.
Assessment of IL-4, IL-6, and IL-12 protein in 1-hour patel-
la washouts. To determine the levels of IL-4, IL-6, and IL-
12 in patella washouts, patellae were isolated in a stan-
dardized manner from knee joints as described
previously (25). Patella were incubated in RPMI 1640
medium (GIBCO BRL, Breda, The Netherlands) with
0.1% BSA, gentamicin (50 m g/mL), and L-glutamine (2
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mM) (200 m L/patella) for 1 hour at room temperature.
After supernatant was harvested the IL-4, IL-6, and IL-
12 levels were measured by ELISA (25, 26). Anti-murine
IL-4 antibodies (Ab’s) were purchased from PharMin-
gen (San Diego, California, USA; capture Ab: rat anti-
mouse IL-4 mAb [clone: BVD4-1D11]; detection Ab: rat
anti-mouse IL-4 mAb biotin labeled [clone: BVD6-
24G2]). The detection range of the IL-4 ELISA is
1,280–1.2 pg/mL. The sensitivity of the IL-4 ELISA is 5
pg/mL. No cross-reactivity was found with the
cytokines IL-1, IL-6, or IL-10. Anti-murine IL-6 Ab’s
were from Biosource International (Camarillo, Califor-
nia, USA; capture Ab: rat anti-mouse IL-6 mAb [clone:
MP5-20F3]; detection Ab: rat anti-mouse IL-6 mAb
biotin labeled [clone MP5-32CK]). The detection range
of the IL-6 ELISA is 2,560–40 pg/mL, with a sensitivity
of 78 pg/mL. No cross-reactivity was found with the
cytokines IL-1 b , IL-4, and IL-10. Anti-murine IL-12
Ab’s were obtained from Genzyme (Cambridge, Mass-
achusetts, USA; capture Ab: monoclonal rat anti-
mouse IL-12 [clone C15.6]; detection Ab: monoclonal
rat anti-mouse IL-12 biotin labeled [clone C17.8]). The
detection range of the IL-12 ELISA is 1,280–1.2 pg/mL,
with a sensitivity of 10 pg/mL. No cross-reactivity was
found with IL-4, IL-6, TNF- a, and IL-1.
Briefly, ELISA plates (Maxisorb; Nunc, Copenhagen,
Denmark) were coated with the capture Ab (3 m g/mL)
by overnight incubation at 4°C in 0.1 M carbonate
buffer (pH 9.6). Nonspecific binding sites were blocked
by 1-hour incubation at 37°C with 1% BSA in
PBS/Tween-20. The supernatants were tested by 3-hour
incubation at 37°C. The plates were then incubated at
37°C with the biotin-labeled second Ab (0.25 m g/mL)
diluted in PBS/0.5% BSA (pH 7.5), followed by a 30-
minute incubation at 37°C with streptavidin conju-
gated to poly-horseradish peroxidase (0.25 m g/mL)
(source: Streptomyces avidinii; Central Laboratory of
Blood Transfusion, Amsterdam, The Netherlands)
diluted in 1% casein colloid/PBS buffer (pH 7.5) (Cen-
tral Laboratory of Blood Transfusion). Bound com-
plexes were detected by reaction with 0.08%
orthophenylenediamine (OPD) diluted in 50 mM
phosphate buffer (pH 6.0) and 0.03% H2O2.
Absorbance was measured at 492 nm using an ELISA
plate reader (Titertek Multiscan MCC/340; Labsys-
tems, Helsinki, Finland). The cytokine concentration
in the samples was calculated as picograms per milli-
liter using recombinant murine IL-4 (a kind gift of S.
Smith [Schering-Plough, Kenilworth, New Jersey,
USA]), IL-6 (Biosource International) and IL-12 (kind-
ly provided by S. Wolf, Genetic Institute Inc., Cam-
bridge, Massachusetts, USA) as a standard.
Isolation of RNA. Mice were sacrificed by cervical dis-
location, and the patella and adjacent synovium were
immediately dissected (39). Synovium biopsy tissue
was taken from six patella specimens. Two biopsy spec-
imens with a diameter of 3 mm were punched out,
using a biopsy punch (Stifle, Wachtersbach, Germany):
one from the lateral side and one from the medial side.
Three lateral and three medial biopsy samples were
pooled to yield two samples per group. The synovium
samples were immediately frozen in liquid nitrogen.
Synovium biopsy samples were ground to powder
using a microdismembrator II (Braun Inc., Melsungen,
Germany). Total RNA was extracted in 1 mL of Trizol
reagent (GIBCO BRL), a monophasic solution of phe-
nol and guanidine isothiocyanate, which is an
improved single-step RNA isolation method based on
the method described by Chomczynski and Sacchi (40).
PCR amplification. One microgram of synovial RNA
was used for RT-PCR. Messenger RNA was reverse tran-
scribed to complementary DNA (cDNA) using oligo-
dT primers, and one twentieth of the cDNA was used
in one PCR amplification. PCR was performed at a
final concentration of 200 m M dNTPs, 0.1 m M of each
primer, and 1 unit of Tag polymerase (GIBCO BRL) in
standard PCR buffer (20 mM Tris-HCL [pH 8.4] and 50
mM KCl) (GIBCO BRL). The mixture was overlaid with
mineral oil and amplified in a thermocycler (Omni-
gene, Hybaid, United Kingdom). Message for GAPDH
was amplified using the primers described elsewhere
(24). Primers for cathepsin K, IL-17, IL-12, OPGL and
osteoprotegerin (OPG) were designed using Oligo 4.0
and Primer Software (Molecular Biology Insights Inc.,
Cascade, Colorado, USA). For every mediator that is
tested in the PCR reaction, GAPDH expression was also
measured in the same reaction mix. Samples (5 m L)
were taken from the reaction tubes after a certain num-
ber of cycles. PCR products were separated on 1.6%
agarose and stained with ethidium bromide. The
expression for GAPDH is normalized between the con-
trol vector group and the IL-4 group before differences
in mRNA expression for a particular mediator were
determined.
Radiology. At the end of the experiment, knee joints
were isolated and used for x-ray analysis as a marker for
joint destruction. X-ray films were carefully examined
using a stereo microscope, and joint destruction was
scored on a scale of 0–5, ranging from no damage to
complete destruction of the joint.
Tartrate-resistant acid phosphatase staining. At the end of
the experiment, whole knee joints were fixed for 2
days in 10% formalin, followed by decalcification in
10% EDTA (Titriplex III; Merck, Darmsadt, Germany)
in 1 mM Tris-HCl (pH 7.4) for up to 2 weeks at 4°C
(10). Decalcified specimens were processed for paraf-
fin embedding (41). Staining of tissue sections (7 m m)
for tartrate-resistant acid phosphatase (TRAP) was
performed by a leukocyte acid phosphatase kit, a cell-
staining kit for the detection of tartrate resistant acid
phosphatase from Sigma Chemical Co. (St. Louis,
Missouri, USA).
Histology. Whole knee joints were removed and fixed
for 4 days in 10% formalin. After decalcification in 5%
formic acid, the specimens were processed for paraffin
embedding (41). Tissue sections (7 m m) were stained
with hematoxylin and eosin (H&E) or Safranin O.
Histopathological changes were scored using the fol-
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lowing parameters. Infiltration of cells was scored on a
scale of 0–3, depending on the amount of inflammato-
ry cells in the synovial cavity (exudate) and synovial tis-
sue (infiltrate). A characteristic parameter in CIA is the
progressive loss of bone. This destruction was graded
on a scale of 0–3, ranging from no damage to complete
loss of the bone structure.
Histopathological changes in the knee joints were
scored in the patella and femur/tibia regions on five
semiserial sections of the joint, spaced 70 m m apart.
Immunohistochemistry was quantified using an auto-
mated image analysis system (Leica Q500/N; Leica
Imaging Systems Ltd., Cambridge, United Kingdom).
Microscopic images were recorded by a CDD video cam-
era (Victor Company of Japan Ltd., Tokyo, Japan) and
processed by a personal computer. Optical density was
measured in the cartilage or synovium. For cartilage, the
whole area of noncalcified cartilage was scanned, and
staining was expressed per unit of tissue (m m2). For syn-
ovium, a defined area along the cortical bone was
scanned, using a standardized template. Five sections
per joint were scanned. Staining values were corrected
for background staining, as measured in the control
vector group. Scoring was performed by two observers
without knowledge of the experimental group, as
described earlier (24).
Immunohistochemistry of OPGL. Whole knee joints were
fixed, decalcified and paraffin embedded as already
describe here. Tissue sections (7 m m) were treated with
1% H2O2 for 10 minutes at room temperature. Sections
were incubated for 1 hour with the primary Ab RANKL
(goat polyclonal Ab raised against a peptide mapping
at the NH2-terminus of RANKL (RANK ligand) of
mouse origin (N-19; Santa Cruz Biotechnology Inc.,
Santa Cruz, California, USA) or a control goat IgG Ab
(Jackson ImmunoResearch Laboratories, West Grove,
Pennsylvania, USA). After rinsing, sections were
blocked with 4% normal mouse serum for 20 minutes
at room temperature. Thereafter, sections were incu-
bated for 30 minutes with biotinylated mouse anti-goat
IgG (Jackson ImmunoResearch Laboratories) and
detected using biotin-streptavidin/peroxidase staining
(Elite kit; Vector Laboratories, Burlingame, California,
USA). Development of the peroxidase staining was
done with 3 ¢ ,3 ¢ diaminobenzidine (Sigma Chemical
Co.). Counterstaining was done with Mayer’s hema-
toxylin.
Immunohistochemical staining of type II collagen neoepi-
topes. Whole knee joints were fixed for 2 days in 10% for-
malin, followed by decalcification in 10% EDTA
(Titriplex III), 7.5% polyvinylpyrrolidone (PVP; Mr
29,000; Serva, Amsterdam, The Netherlands) in 0.1M
phosphate buffer (pH 7.4) for 2 weeks at 4°C. After
extensive rinsing with 7.5% PVP in 0.1M phosphate
buffer, tissue blocks were rapidly frozen in liquid nitro-
gen and stored at –70°C. Whole knee joint sections (7
m m) were cut at 22°C on a micron cryostat and mount-
ed on glass microscope slides precoated with 3-amino-
propyltriethoxysilan (Sigma Chemical Co.). Sections
were dried for 1 hour and stored at –70°C until further
use. After thawing, the sections were fixed in freshly
prepared 4% formaldehyde (5 minutes) and washed
extensively in 0.1 M PBS (pH 7.4) for 15 minutes. Sec-
tions were incubated with 1% hyaluronidase (type I-s;
Sigma Chemical Co.) for 30 minutes at 37°C, to
remove proteoglycans. After treatment with 1% H2O2
for 30 minutes, nonspecific staining was blocked by
incubation with 10% normal goat serum with 1% BSA.
Sections were incubated overnight with the primary
rabbit Ab Col2-3/4Cshort (kindly provided by A.R. Poole
[McGill University, Montreal, Canada]) directed
against the COOH-terminal neoepitope generated by
cleavage of native human type II collagen by collage-
nases, which has been described and characterized pre-
viously (42). The Col2-3/4Cshort antiserum detects the
COOH-terminal neoepitope that can be generated by
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Figure 1
Adenoviral vector–mediated IL-4 expression in the mouse knee joint. (a) 1.107 pfu of Ad5E1mIL-4 was given intra-articularly to naive C57bl/6
mice and patella with adjacent synovium was taken in a standardized manner on days 1, 2, 4, 7, and 14 to measure IL-4 in the washouts of
joint tissue by ELISA. The control vector of the same dose and the washouts from the contralateral knee both gave rise to undetectable lev-
els of IL-4 (not graphed). Results are expressed as mean – SD of four mice per time point. (b) Various doses of AdE1mIL-4 were given intra-
articularly to naive C57bl/6 mice, and IL-4 was measured in washouts of joint tissue at day 7 by ELISA. Results are expressed as mean – SD
of four mice per dose. The detection limit of the mIL-4 ELISA is 5 pg/mL.
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matrix metalloprotease-1 (MMP-1), MMP-8, MMP-13,
and probably also by MMP-2 (43). After extensive rins-
ing, sections were incubated with biotinylated goat
anti-rabbit IgG and detected using biotin-strepta-
vidin/peroxidase staining (Elite kit). Development of
the peroxidase staining was done with
3 ¢ ,3 ¢ diaminobenzidine (Sigma Chemical Co.). Coun-
terstaining was done with Mayer’s hematoxylin.
Preparation of bone fragments. Rheumatoid bone sam-
ples were obtained from patients with osteoarthritis
(OA) and RA, according to the revised criteria of the
American College of Rheumatology (44), who were
undergoing knee or wrist synovectomy, or joint replace-
ment. Bone fragments were prepared as described pre-
viously (30). Samples were cut into small pieces of
approximately 2 mm3 and incubated in triplicate in
complete medium consisting of MEM medium
(GIBCO BRL), 2 mM L-glutamin, 100 U/mL penicillin,
50 mg/mL gentamicin, 20 mM HEPES buffer, and 10%
FCS. Cultures were performed at 37°C in a 5%
CO2/95% humidified air. Bone fragments were cul-
tured in 24-well plates (Falcon, Oxnard, CA) in a final
volume of 2 mL. The cytokines to be tested were added
at the beginning of the culture.
Measurement of collagen degradation. Type I collagen C-
telopeptide breakdown products (CTX) were measured
in synovium piece culture supernatants by a two-site
ELISA (Serum Crosslaps One-Step, Osteometer
Biotech, Ballerup, Denmark) using two mAb’s raised
against a synthetic peptide with an amino acid
sequence specific for a part of the C-telopeptide of a 1-
chain of type I collagen (45). Intra- and interassay CVs
are lower than 5% and 8%, respectively, and the sensi-
tivity is 154 pmol/L.
Determination of type I collagen production. The produc-
tion of type I collagen was estimated in 48-hour culture
media by measuring the concentration of the C-propep-
tide of type I collagen (PICP) using a two-site ELISA that
uses an mAb and a polyclonal Ab raised against human
PICP purified from skin fibroblast cultures (Procolla-
gen-C, Metra Biosystem Inc., Palo Alto, California, USA)
(46, 47). The sensitivity of the assay is 1 ng/mL, and the
intra- and interassay CV were below 7%.
Statistical analysis. Means – SD of the various groups
were determined and potential differences between
experimental groups were tested using the Mann-Whit-
ney rank sum test, unless stated otherwise.
Results
Intra-articular Ad5E1mIL-4 gene transfer in the mouse knee
joint. Naive C57bl/6 mice were intra-articularly inject-
ed in the right knee joint with 1.107 pfu of Ad5E1mIL-
4, and IL-4 levels were measured at different time
points in washouts of joint tissue. This dose of aden-
ovirus did not induce joint inflammation in a knee
joint of naive mice (48). Low levels of IL-4 were found
the first 2 days after a single injection of Ad5E1mIL-4,
after which IL-4 levels increased in time (Figure 1a).
The same expression pattern was found in IL-4 gene
knockout mice (data not shown), indicating that rise of
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Figure 2
Kinetic study of the course of collagen arthritis in the knee joint after
intra-articular injection of Ad5E1mIL-4 and Ad5del70-3. Collagen
type II–immunized DBA-1 mice were injected intra-articularly in the
right knee joint with 1.107 pfu of either Ad5E1mIL-4 or Ad5del70-3
before onset of CIA was noted. At days 1, 3, 5, and 7 after intra-artic-
ular injection of the viral vector, mice were sacrificed by cervical dis-
location, and the skin of the knee joint was removed. The appearance
of arthritis in the injected joints was visually scored for severity
(arthritis score). Results are the mean – SD of two separate experi-
ments with a total of at least 22 mice per group. Ad control,
Ad5del70-3.
Figure 3
Analysis of the inflammatory aspects of local IL-4 overexpression in
the knee joint of mice with collagen-induced arthritis. Knee joints
were taken for histology. Synovial infiltrate and exudate were scored
on a scale of 0–3. Results are the mean – SD of four separate exper-
iments with at least eight mice per group per experiment. For details,
see Figure 2.
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IL-4 levels in time was not due to autoinduction of IL-
4. The adenoviral vector–mediated IL-4 expression in
the mouse knee joint was vector dose related (Figure
1b). No detectable levels of IL-4 were found in
washouts from the contralateral knee or the Ad5del70-
3 control vector injected knee or in sera from
Ad5E1mIL-4–injected animals (data not shown).
Intra-articular Ad5E1mIL-4 gene transfer in the knee joint
of CII-immunized mice. DBA-1 mice were immunized
with CII, and shortly before expected onset of collagen
arthritis, a single injection of 1.107 pfu of Ad5E1mIL-4
or control vector was given in the right knee joint. At
days 7 and 14 after the intra-articular injection of
Ad5E1mIL-4, relatively high IL-4 levels (333 – 105 and
416 – 230 pg/mL, respectively) were measured in
washouts of joint tissue of the IL-4 group. No
detectable IL-4 was noted in washouts of the knee
joints injected with the control vector (Ad5del70-3). No
difference was noted in the course of the collagen
arthritis in the injected knee joints between the IL-4
group and the control vector group (Figure 2). In line
with our previous study (26), at day 7, a 100% arthritis
incidence was noted in the right knee joint of the IL-4
group with a severity score of 2.0 – 0.2 compared with
90% incidence in the control vector group with an
arthritis score of 1.8 – 0.6 (Figure 3). No obvious dif-
ferences in severity were found in the infiltrate and exu-
date between the Ad5E1mIL-4 group and the
Ad5del70-3 control group (Figure 3).
IL-4 prevents collagen breakdown during collagen arthritis.
Collagen breakdown leads to irreversible joint damage.
We investigated the impact of local IL-4 application on
collagen breakdown during collagen arthritis. Histo-
logical knee joint sections were stained with Ab’s rec-
ognizing type II collagen breakdown neoepitopes. We
found less collagen type II breakdown neoepitope
expression in the IL-4 group compared with the control
group (72 – 16% [SD] suppression; mean of 10 sam-
ples) (Figure 4), which is in line with our earlier find-
ings that IL-4 prevents cartilage erosion.
Local IL-4 overexpression prevents localized bone erosion
during collagen arthritis. Whole knee joints were radio-
logically scored for the degree of joint destruction.
Seven and 14 days after the viral injection, x-ray analy-
sis showed marked joint destruction in the control vec-
tor group (Figures 5 and 6, b and d). Interestingly, local
IL-4 treatment strongly reduced the degree of joint
destruction (75%) (P < 0.001) (Figure 5). At days 7 and
14 after the viral injection, marked prevention of joint
damage was still noted in the IL-4 group compared
with the control vector group (Figure 6, c and e). In
addition, mice were ranked for individual scores of
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Figure 4
Effects of local IL-4 on collagen breakdown. (a)
Arthritic knee joint of a mouse 7 days after intra-artic-
ular injection of 1.107 pfu of Ad5del70-3 showing
staining for type II collagen breakdown epitope,
detected with mAb Col2-3/4Cshort. (b) Knee joint of a
mouse 7 days after intra-articular injection of 1.107
pfu of Ad5E1mIL-4. Note the decreased staining of
collagen type II breakdown epitope. a and b, · 250.
Figure 5
X-ray analysis of joint damage in CIA after one intra-articular injec-
tion of Ad5E1mIL-4. Immunized DBA-1 mice were injected intra-
articularly in the right knee with 1.107 pfu of Ad5E1mIL-4 or
Ad5del70-3 before onset of CIA was noted. Seven days later, mice
were sacrificed by cervical dislocation, and the knee joints were taken
for x-ray analysis. Joint damage was scored on a scale of 0–5. Results
are the mean – SD with 12 mice per group. AP < 0.001 versus control
group, by Mann-Whitney rank sum test.
Table 1
Classification of individual mice, with respect to degree of joint
destruction after Ad5E1mIL-4 treatmentA
Joint destructionB
Ad5del70-3 Ad5E1mIL-4C
None 0 5
Mild 4 7
Marked 4 0
Severe 4 0
ASee Figure 4 for more detail on the experimental protocol. BArthritic mice were
classified according to their degree of joint destruction, as scored radiologically
on whole knee joints. Whole knee joints were scored using a scale of no changes
(none), minor destruction, one spot per area (mild), marked changes in more
areas ( marked), and severe erosions afflicting the joint (severe). c 2 test showed
significance (P < 0.001) between Ad5E1mIL-4 and Ad5del70-3 treatment com-
paring none/mild and marked/severe groups. CNumber of mice.
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joint destruction in four subclasses (Table 1). Whereas
the majority of mice of the control group were ranked
as having severe destruction, none of the mice of the IL-
4 group was in this category. All mice of the IL-4 group
were ranked as having no or mild destruction.
A characteristic histological parameter in collagen
arthritis is the progressive loss of bone at the joint mar-
gins. Subchondral and cortical bone destruction was
scored on semiserial knee joint sections in the patella
and femur/tibia region. Hyperplastic synovial tissue,
consisting of synoviocytes extends over the cortical
bone surface of the patella and femur/tibia in the
arthritic control group and the IL-4–treated group
(Figure 7a). Profound bone erosions were found in the
control, arthritic group (Figures 7b, and 8, a–d).
Destruction of subchondral bone in the patella and
femur region was noted (Figure 7c). Lateral and medi-
al sites of the cortical bone of the patella and several
parts of the femur/tibia were completely eroded (Fig-
ure 7d). Synoviocytes were noted in the erosion front.
Inflammatory tissue seems to invade into the bone at
sites of bone erosion. Of high interest, despite the lack
of difference in hyperplasia of synovial tissue that
extends over the bone surface (Figure 7a), the degree of
bone erosion was highly reduced in the IL-4–treated
group (P < 0.001) (Figures 7 and 8, e–h). Mean values of
two separate experiments revealed 70% and 68% reduc-
tion for this parameter in the subchondral bone of the
patella and femur/tibia, respectively, and 58% and 62%
reduction in the cortical bone of the patella and
femur/tibia, respectively, in the IL-4 group compared
with its respective adenoviral vector group.
Effects of IL-4 on osteoclast-like cells. Osteoclasts are
potent bone resorbing cells and play an important
role in joint destruction. TRAP activity is a character-
istic phenotypic marker of osteoclasts and osteoclast
precursors and is expressed in osteoclast-like cells in
murine collagen-induced arthritis (10). To demon-
strate further the protective effect of local IL-4, TRAP
staining was performed on paraffin-embedded knee
joint sections. TRAP-positive mononuclear cells were
found in the erosive front in the control vector group
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Figure 6
Effects of Ad5E1mIL-4 on joint damage and bone structure in CIA. (a) Knee joint of a naive DBA-1 mouse. (b and d) Arthritic knee joint of
a mouse 7 and 14 days, respectively, after intra-articular injection of 1.107 pfu of Ad5del70-3 control vector. Note the enhanced joint dam-
age and less-compact bone structure (arrows). (c and e) Knee joint of a mouse 7 and 14 days, respectively, after intra-articular injection of
1.107 pfu of Ad5E1mIL-4. Note the prevention of joint damage and the compact bone structure. fe, femur; fi = fibula; ti = tibia.
Figure 7
Histological analysis of bone erosion in CIA after one intra-articular
injection of Ad5E1mIL-4. Immunized DBA-1 mice were injected intra-
articularly in the right knee with 1.107 pfu of Ad5E1mIL-4 or Ad5del70-
3 before onset of CIA was noted. Seven days later, mice were sacrificed
by cervical dislocation, and the knee joints were taken for histology.
Pannus formation (i.e., hyperplastic synovial tissue extending over the
cortical bone surface) (a) and bone erosion (b) were scored on a scale
of 0–3. Loss of subchondral (c) and cortical (d) bone in the patella and
femur/tibia region was separately scored on a scale of 0–3. Results are
the mean – SD of four separate experiments with at least eight mice
per group per experiment. AP < 0.001; BP = 0.003; CP = 0.005 versus
control group, by Mann-Whitney rank sum test.
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(Figure 9, a–d). Local IL-4 overexpression in the knee
joint of CII-immunized mice highly decreased the
number of TRAP-positive mononuclear cells, indicat-
ing that IL-4 inhibits the formation of osteoclast-like
cells (Figure 9, e–h).
The mechanism(s) involved in the formation and
activation of osteoclasts in RA is still unknown. How-
ever, locally produced cytokines in the synovium,
such as IL-1, IL-6, and TNF- a could provide signals
for osteoclast differentiation and bone resorption
(14–17). Local IL-4 gene therapy reduces the IL-1 b
protein level (76%) found in the washouts of synovial
tissue (26). No significant levels of free TNF- a was
found in tissue washouts of either the IL-4–treated
group or the control vector group (data not shown).
IL-6 protein was much lower (56%) in the synovium
washouts of the IL-4–treated group compared with
the control vector group (Figure 10a).
Local IL-4 suppresses IL-17 and OPGL expression in the
synovium. Many of the cytokines known to stimulate
bone resorption act through the upregulation of a
novel and essential factor for osteoclastogenesis,
OPGL (21). OPGL is produced by different cell types,
including activated T cells (49). IL-17 is a T-
cell–derived cytokine that was found in the synovium
of a patient with RA and is a potent stimulator of
osteoclastogenesis (19, 20). To get a better impression
of potential changes in mediators involved in T-
cell–driven activation, we analyzed IL-17 and IL-12
mRNA levels, using RT-PCR. Both cytokines were
strongly reduced in the IL-4–treated mice and marked
reduction of IL-12 protein levels (74%) was found
(Table 2; Figure 10b).
OPGL expression was found in the synovium and
at places where bone erosion takes place using RT-
PCR and immunohistochemistry (Table 2; Figure
11). Intriguingly, OPGL expression was greatly
reduced in the synovium by local IL-4 (Table 2; Fig-
ure 11c: 57 – 12% [SD] suppression, mean of 10
samples). No difference in OPG mRNA expression
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Figure 8
Effects of Ad5E1mIL-4 on bone erosion
in CIA. (a–d) Arthritic knee joint of a
mouse 7 days after intra-articular injec-
tion of 1.107 pfu of Ad5del70-3 control
vector. Note the infiltrate and bone ero-
sion (arrows). (e–h) Knee joint of a
mouse 7 days after intra-articular injec-
tion of 1.107 pfu of Ad5E1mIL-4. Note
the pronounced infiltrate, but preven-
tion of bone erosion. a, b, e, and f, ·
100. c, d, g, and h, · 200. H&E staining
was used. P, patella; F, femur; JS, joint
space; C, cartilage; S, synovium; CB, cor-
tical bone.
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was noted between the IL-4 group and the control
group (Table 2).
Ad5E1mIL-4 suppresses cysteine proteinase cathepsin K
mRNA expression in synovial tissue. Cysteine proteinase
cathepsin K probably is involved in osteoclast-mediat-
ed bone resorption (13, 50). Upregulation of cathepsin
K mRNA expression in RA synovium compared with
normal synovium has been reported (50). Cathepsin K
was not only expressed by osteoclast but also by syn-
ovial fibroblast, suggesting that cathepsin K con-
tributes to bone destruction mediated by RA synovial
cells (50). We investigated the effects of local IL-4 over-
expression on the cathepsin K expression in the syn-
ovial tissue. RT-PCR measurements revealed a strong-
ly reduced level of cathepsin K in the synovial tissue by
Ad5E1mIL-4 (Table 2).
IL-4 prevents collagen type I degradation in bone from patients
with RA and those with OA. The major collagen type found
in bone is type I collagen. The increased rate of bone
destruction is reflected by a COOH-terminal peptide
released during the degradation of type I collagen. The
effects of IL-4 on type I collagen CTX was tested in bone
samples from five patients with RA and four with OA.
CTX was found in the supernatants of these patients.
Incubation with IL-4 for 7 days markedly suppressed
CTX in the supernatant of all patients (mean: 70% for
RA and 65% for OA), indicating that IL-4 strongly pre-
vented collagen type I degradation (Table 3). In addition,
we analyzed the effects of IL-4 on the synthesis of type I
procollagen. It was found in all samples that formation
was enhanced (mean: 77% for RA and 85% for OA), sug-
gesting promotion of tissue repair (Table 3).
Discussion
We clearly demonstrated marked protection against
joint destruction by local IL-4 overexpression in the
inflamed joint. Radiological and histological analysis
revealed pronounced protection against cartilage and
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Figure 9
Effects of Ad5E1mIL-4 on osteoclast-
like cells. (a–d) Arthritic knee joint of a
mouse 7 days after intra-articular injec-
tion of 1.107 pfu of Ad5del70-3 control
vector. Note the TRAP-positive
mononuclear cells in the erosive front
(red). (e–h) Knee joint of a mouse 7
days after intra-articular injection of
1.107 pfu of Ad5E1mIL-4. Note the
decreased number of TRAP-positive
mononuclear cells. e, · 100. a–d and
f–h, · 200. P, patella; F, femur; JS, joint
space; C, cartilage; S, synovium; CB,
cortical bone; TP, tibia plateau.
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bone erosion, despite full-blown arthritis. This protec-
tive effect of local IL-4 was associated with decreased
formation of osteoclast-like cells and downregulation
of IL-17, IL-6, IL-12, OPGL, and cathepsin K expression
in the synovium. Furthermore, IL-4 inhibits the break-
down of type I collagen in bone samples from patients
with arthritis. Interestingly, promotion of tissue repair
by IL-4 was suggested through upregulation of type I
procollagen in these cultures.
Lack of regulatory mediators such as IL-4 may con-
tribute to the uneven balance of destructive and mod-
ulatory mediators in the synovium of the RA process.
Understanding the regulation of the destructive
process, the cytokines and cells that are involved may
provide better therapeutic approaches in patients
with RA. It is now generally accepted that TNF- a and
IL-1 are key mediators in RA, and these proinflam-
matory cytokines play a critical role in the CIA (51).
Studies in animal models identified the pivotal role of
IL-1 in cartilage matrix degradation, whereas TNF- a
plays a major role in the inflammatory process
(51–56). Enhanced IL-1 b protein levels were found in
the arthritic synovial tissue (26), whereas, TNF- a pro-
tein levels were low in both the control vector and IL-
4–expressing vector group, suggesting that IL-1 is
enhancing osteoclast formation in CIA. Of high inter-
est, local IL-4 treatment strongly reduced local IL-1
(26) in the arthritic synovium, indicating that IL-4 is
an important regulator of this destructive mediator.
Protection of bone erosion was associated with
decreased formation of osteoclast-like cells in the IL-
4–treated mice. Locally produced cytokines in the syn-
ovium could provide signals for osteoclast differentia-
tion and bone resorption (14–17). In addition to IL-1,
IL-6 has been shown to be a powerful stimulator of
osteoclast bone resorption. It is produced by the
inflamed synovium and found in large amounts in RA
synovial fluid (57, 58). It can induce osteoclast devel-
opment and was shown to be directly involved in bone
resorption in an in vivo model of osteoporosis, related
to estrogen loss (59). Anti–IL-6 is inhibitory to osteo-
clast-like cell formation (10). In the present study, we
found marked reduction of IL-6 in the arthritic syn-
ovium tissue after local IL-4 treatment, indicating that
the mechanism of decreasing the number of osteoclast-
like cells by local IL-4 treatment may, at least in part, be
mediated by suppressing this important osteoclast
stimulator. It is not yet clear whether IL-4 directly
reduced IL-6 production or whether this is a result of
marked suppression of IL-1 (26).
Osteoclasts differentiate from hematopoietic
monocyte/macrophage precursors (4, 21). It has been
demonstrated that osteoclast formation can occur in
the absence of any bone or bone marrow–derived cells
(60). Furthermore, it has been shown that synovial
macrophages are capable of differentiating into
osteoclasts in the presence of rheumatoid synovial
fibroblasts (60), revealing that rheumatoid synovial
cells contain both osteoclast progenitors and stromal
cells supporting their differentiation (60). OPGL may
play an important role in this differentiation path-
way, as OPGL is considered a novel key regulator of
osteoclastogenesis (21). Many of the cytokines
known to stimulate bone resorption act through the
upregulation of this novel and essential factor. The
synovial lining is normally a thin layer, one to two
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Figure 10
Local IL-4 overexpression in the knee joint of collagen type II–immu-
nized mice suppresses local IL-6 and IL-12 protein levels. Collagen
type II–immunized mice with a booster injection on day 22 were
injected in the right and left knee joint on day 26 with 1.107 pfu of
Ad5E1mIL-4 or Ad5del70-3 before onset of CIA was noted. Seven
days after the intra-articular injection of the adenoviral vector, patel-
la with adjacent synovium were isolated in a standardized manner
from the knee joints and cultured for 1 hour in 200 m L RPMI 1640
with 0.1% BSA medium at room temperature. IL-6 and IL-12 levels
were measured in these culture supernatants using a specific ELISA.
Results are the mean – SD of eight and nine patella washouts per
group for IL-6 and IL-12, respectively. AP = 0.04 versus control group,
by Mann-Whitney rank sum test.
Table 2
Synovial mRNA levels after Ad5E1mIL-4 treatmentA
PCR cyclesB
Synovium
Ad5del70-3C Ad5E1mIL-4C D D
IL-17 34 > 42 –8
IL-12 30 36 –6
OPGL 30 34 –4
OPG 30 30 0
Cathepsin K 30 35 –5
ASynovial mRNA levels were determined by RT-PCR technology, 7 days after
the viral injection. Total RNA from six synovium biopsies of three mice were
pooled, yielding two samples per group, as described in Methods. Values are
the mean of two experiments with 12 mice per group. The PCR measurements
of a particular mediator were routinely repeated three times. Samples (5 m L)
were taken at two-cycle intervals, with a total of six samples applied to the gel.
The variations in the two repeated experiments never exceeded more than two
cycles. BNumber of PCR cycles in which gene product of interest was first
detectable. CImmunized DBA-1 mice were injected intra-articularly in the right
knee joint with 1.107 pfu of Ad5E1mIL-4 or Ad5del70-3, before onset of CIA
was noted. Messenger RNA expression was determined 7 days after the viral
injection. D D refers to the difference between the respective Ad5del70-3– and
Ad5E1mIL-4–treated conditions.
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cells in thickness, which consist of type A and B cells,
showing macrophages and fibroblast-like properties.
During (chronic) joint inflammation, considerable
thickening of the lining is a characteristic event, and
the subsynovial tissue becomes infiltrated by numer-
ous macrophages and lymphocytes. Therefore, osteo-
clasts differentiated from monocyte/macrophage
precursors in the synovial membrane are probably
involved in bone destruction in arthritis. Interest-
ingly, we found OPGL expression in the synovium
and at sites where bone erosion takes place in the
arthritic control group. Furthermore, we found
osteoclast-like cells in the erosive front in the knee
joint of the arthritic control mice showing severe
joint destruction, which is compatible with an earli-
er study demonstrating direct participation of osteo-
clast-like cells in the joint destruction of CIA (10).
Moreover, at bone erosion sites, the receptor of
OPGL, RANK was expressed in areas were OPGL
expression was found (E. Lubberts et al., manuscript
in preparation). Remarkably, local IL-4 treatment
suppressed OPGL expression and highly reduced
numbers of osteoclast-like cells, suggesting that local
IL-4 overexpression interferes in the differentiation
pathway of macrophage precursors to osteoclasts.
We found reduced numbers of osteoclast-like cells
after local IL-4 treatment, whereas the amount of
inflammatory cells in the synovial tissue was not
reduced. A similar situation has been described in
osteomyelitis, where reduced osteoclast activity was
observed in bone adjacent to infection, without a
notable decrease in the inflammatory mass (61). This
suggests that the inflammatory cells can be there, but
do not necessarily display a destructive phenotype. It
was shown that the T-cell–derived cytokine IL-17,
which is expressed in the synovium of patients with
RA (19, 20), is a potent stimulator of osteoclastogen-
esis (19). To get a better impression of potential
changes in mediators involved in T-cell–driven acti-
vation, we analyzed IL-12 and IL-17 levels. Both
cytokines were strongly reduced in the IL-4–treated
mice. Activated, but not resting, T cells can directly
trigger osteoclastogenesis through OPGL (49), and, as
already discussed, also OPGL mRNA expression was
greatly reduced. Interestingly, no difference was
found in OPG expression between the control group
and the IL-4 group, suggesting that IL-4 suppresses
the OPGL/OPG balance. These data indicate that T-
cell–driven OPGL production is a pivotal element in
bone erosion in collagen arthritis and that IL-4
inhibits this process either directly, or through down-
regulation of cytokines involved in T-cell maturation
and mediator production. Investigation into further
characterization of the IL-12, IL-17, and OPGL inter-
play is currently under way. 
Cysteine proteinase cathepsin K expression is high-
ly tissue specific and is predominantly expressed in
osteoclasts (62, 63) and fibroblasts, but hardly in
macrophages (50). Cathepsin K has been suggested to
be a key enzyme in diseases associated with excessive
loss of bone (50). In the present study, we found
marked reduction of mRNA expression of cathepsin
K in synovial tissue by local IL-4, which is in line with
reduced numbers of osteoclast-like cells. In addition,
it implies that IL-4 may have a direct effect on the
cathepsin K production in fibroblasts.
In most metabolic bone diseases, both bone forma-
tion and bone resorption are altered. To analyze these
elements in bone samples of patients with arthritis,
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Figure 11
Effects of IL-4 on OPGL expression in the synovium. (a and b)
Arthritic knee joint of a mouse 7 days after intra-articular injection
of 1.107 pfu of Ad5del70-3 control vector showing staining for
OPGL, detected with a control anti-goat Ab (a) or the anti-RANKL
Ab (b). Note the OPGL expression in the synovium and in cells
along the cortical bone. (c) Knee joint of a mouse 7 days after
intra-articular injection of 1.107 pfu of Ad5E1mIL-4 showing stain-
ing for OPGL, detected with the anti-RANKL Ab. Note the
decreased OPGL expression in the synovium and in cells along the
cortical bone. a–c, · 250. S, synovium; CB, cortical bone.
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we have taken the same biochemical assays as are used
routinely in bone metabolic studies. This includes the
measurement of PICP as a marker of procollagen syn-
thesis by osteoblasts and CTX, a COOH-terminal pep-
tide, as a marker of type I collagen degradation
(64–66). Earlier studies already indicated that high
serum and urinary levels of CTX reflect increased
bone destruction in patients with RA, and a positive
correlation with x-ray destruction was demonstrated
(67). In the present study, we show that IL-4 can sup-
press CTX release in cultures of bone explants of
patients with arthritis, but also enhanced the forma-
tion of type I procollagen. As such, IL-4 exerts a dual
positive effect. This adds clinical relevance to the con-
vincing protective effect noted with IL-4 in the colla-
gen arthritis model.
Cartilage damage is usually linked to bone erosion,
and MMPs are crucial in late, irreversible cartilage dam-
age. In the present study, we confirmed the cartilage
protective effect of local IL-4 (26) and found less colla-
gen type II breakdown neoepitope expression, which
can be generated by MMP-1, -8, -13, and probably also
by MMP-2 (43). This suggests that IL-4 reduces colla-
genase activity, either directly or through reduction of
stromelysin-1, which is essential in collagenase activa-
tion. Further characterization of the IL-4 effect on
MMP activity is warranted.
Previous studies from our group have revealed the
potential uncoupling of inflammation and joint
destruction. TGF- b showed enhanced fibrosis but
ameliorated cartilage damage (68). In addition, selec-
tive elimination of synovial lining cells with toxic lipo-
somes can prevent the expression of joint inflamma-
tion; however, this treatment is not necessarily
protective against cartilage damage (68). Further-
more, OPG treatment in adjuvant-induced arthritis
completely abolished the loss of mineral bone densi-
ty however, had no effect on the severity of inflam-
mation (49). Another important demonstration
showing protection of the skeleton from damage
when inflammation is essentially unaffected was
reported by Bresnihan et al. (69). In this human clin-
ical study with IL-1 receptor antagonist, beneficial
effect on the rate of joint erosion was shown,
although the inflammation was not significantly
arrested. The present study clearly shows uncoupling
of inflammation and surface erosion of bone and car-
tilage. All of this underscores the concept that the bal-
ance of destructive and protective mediators deter-
mines the relative erosive nature of a given arthritis,
rather than the bulk of the inflammatory mass.
In conclusion, this is the first report demonstrating
clear bone protective effects of local IL-4 gene therapy
in experimental arthritis, despite severe inflammation.
Furthermore, IL-4 prevented collagen type I degrada-
tion in bone samples of patients with arthritis, and
interestingly, it stimulated the formation of type I pro-
collagen. Because the control of bone destruction is the
most difficult target in the treatment of patients with
arthritis, our data have significant implications for the
prevention of bone erosion in arthritis.
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